W Health Ventures Fund II: ~$80M Final Close at ₹700 Cr for Company Creation

W Health Ventures closed Fund II at ₹700 crore (~US$80 million) — above its ₹630 crore target — according to September 8, 2026 coverage (Indian Startup Times). That follows a February 2026 ₹550 crore first close (Economic Times).

Spine: this is a company-creation vehicle, not a classic spray-and-pray seed fund — physicians and operators incubate the thesis before a founding team is hired.

Key facts

Firm

W Health Ventures (Mumbai, Bengaluru, Delhi, Boston)

Fund

Fund II final close ₹700 Cr (~$80M)

Prior milestone

First close ₹550 Cr (Feb 2026); target was ₹630 Cr

Model

12–18 months internal de-risking → founding team

Pace plan

8–10 companies / four years; ₹30–50 Cr per incubation; 2–3/year

Fund II launches cited

Everhope Oncology (with Narayana Health); Everbright Health (US TRD clinics)

Firm claim

Portfolio companies reached 25M patients to date

Who this capital serves

Patients/providers: new category companies in oncology, psychiatry, chronic care, and related gaps where WHV believes first-mover coordinated care beats incremental clinic SaaS.

Founding CEOs: operators plugged into a pre-diligence thesis rather than a blank-sheet seed.

LPs: healthcare specialists who want India + US-India corridor exposure with operational involvement baked in.

Why now

• India healthcare demand is scaling faster than coordinated specialty capacity (oncology, obesity, mental health).
• Cross-border US-India psychiatry/oncology plays need patient capital that can wait through incubation.
• Completing above target after a February first close suggests LP demand for builder funds outpaced the original ₹630 Cr ask.

What is not proven

• LP roster and management fees were not detailed in the IST piece.
• “25 million patients” is a firm claim across the portfolio, not Fund II alone.
• FX on ~$80M is illustrative (~₹87.5/$); lead with ₹700 Cr as the disclosed close figure.

Implication

WHV’s scoreboard is companies launched and clinical outcomes, not deal count. Watch whether Everhope and Everbright raise external growth capital on schedule — that is how Fund I was validated.